Xenon Pharmaceuticals (XENE) Stock Forecast & Price Target $35.34 -1.16 (-3.18%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$35.19 -0.15 (-0.42%) As of 10/23/2026 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Xenon Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 15 Analyst RatingsSell1Hold1Buy13 Based on 15 Wall Street analysts who have issued ratings for Xenon Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 1 has given a sell rating, 1 has given a hold rating, 12 have given a buy rating, and 1 has given a strong buy rating for XENE. Consensus Price Target $70.1498.48% Upside According to the 15 analysts' twelve-month price targets for Xenon Pharmaceuticals, the average price target is $70.14. The highest price target for XENE is $97.00, while the lowest price target for XENE is $46.00. The average price target represents a forecasted upside of 98.48% from the current price of $35.34. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for XENE and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Xenon Pharmaceuticals and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XENE Analyst Ratings Over TimeTypeCurrent Forecast10/24/25 to 10/24/261 Month Ago9/24/25 to 9/24/263 Months Ago7/26/25 to 7/26/261 Year Ago10/24/24 to 10/24/25Strong Buy1 Strong Buy rating(s)2 Strong Buy rating(s)2 Strong Buy rating(s)1 Strong Buy rating(s)Buy12 Buy rating(s)13 Buy rating(s)14 Buy rating(s)10 Buy rating(s)Hold1 Hold rating(s)1 Hold rating(s)0 Hold rating(s)0 Hold rating(s)Sell1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)Consensus Price Target$70.14$70.93$77.20$53.67Forecasted Upside98.48% Upside86.37% Upside18.01% Upside31.67% UpsideConsensus RatingModerate BuyModerate BuyBuyModerate Buy XENE Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History XENE Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Xenon Pharmaceuticals Stock vs. The CompetitionTypeXenon PharmaceuticalsHealthcare CompaniesBroader MarketConsensus Rating Score 2.87 2.32 2.53Consensus RatingModerate BuyHoldModerate BuyPredicted Upside98.48% Upside1,400.11% Upside16.91% UpsideNews Sentiment RatingNeutral NewsSee Recent XENE NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings Most Recent from Each Brokerage All Show All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action 10/24/2024 - 10/24/2026 Report Date Report Date From Report Date To 1M3M6MYTD1Y2Y3Y5Y More filters Fewer filters Done 0 Results Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails10/6/2026 Guggenheim5 of 5 starsDelma CaiatiNot RatedInitiated CoverageBuy$73.00+94.30%10/2/2026 Weiss Ratings3 of 5 stars Reiterated RatingSell (D-)9/28/2026 Jefferies Financial Group3 of 5 starsAndrew Tsai5 of 5 starsReiterated RatingBuy$90.00+143.64%9/18/2026 HC WainwrightSubscribe to MarketBeat All Access to unlock brokerage rankingsDouglas TsaoSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingBuy9/18/2026 Wells Fargo & CompanySubscribe to MarketBeat All Access to unlock brokerage rankingsBenjamin BurnettSubscribe to MarketBeat All Access to unlock analyst rankingsLower TargetOverweight$69.00 ➝ $64.00+11.60%9/18/2026 Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access to unlock brokerage rankingsDavid HoangSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingBuy ➝ Hold$90.00 ➝ $46.00-19.79%9/18/2026 Royal Bank Of CanadaSubscribe to MarketBeat All Access to unlock brokerage rankingsBrian AbrahamsSubscribe to MarketBeat All Access to unlock analyst rankingsLower TargetOutperform$81.00 ➝ $70.00+70.02%9/18/2026 WedbushSubscribe to MarketBeat All Access to unlock brokerage rankingsLaura ChicoSubscribe to MarketBeat All Access to unlock analyst rankingsLower TargetOutperform$71.00 ➝ $55.00+24.78%9/18/2026 Robert W. BairdSubscribe to MarketBeat All Access to unlock brokerage rankingsBrian SkorneySubscribe to MarketBeat All Access to unlock analyst rankingsLower TargetOutperform$97.00 ➝ $90.00+56.93%9/18/2026 Needham & Company LLCSubscribe to MarketBeat All Access to unlock brokerage rankingsSerge BelangerSubscribe to MarketBeat All Access to unlock analyst rankingsLower TargetBuy$78.00 ➝ $60.00+4.62% Get the Latest News and Ratings for XENE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 5/27/2026 JPMorgan Chase & Co.Subscribe to MarketBeat All Access to unlock brokerage rankingsTessa RomeroSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOverweight$80.00 ➝ $82.00+51.25%3/9/2026 Morgan StanleySubscribe to MarketBeat All Access to unlock brokerage rankings Set Target$97.00+54.56%3/9/2026 Bank of AmericaSubscribe to MarketBeat All Access to unlock brokerage rankings Reiterated RatingBuy2/23/2026 Wolfe ResearchSubscribe to MarketBeat All Access to unlock brokerage rankingsRudy LiSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageOutperform$60.00+40.45%2/10/2026 Stifel NicolausSubscribe to MarketBeat All Access to unlock brokerage rankings Set Target$66.00+55.55%11/19/2025 Chardan CapitalSubscribe to MarketBeat All Access to unlock brokerage rankingsRudy LiSubscribe to MarketBeat All Access to unlock analyst rankingsUpgradeStrong-Buy11/4/2025 Cantor FitzgeraldSubscribe to MarketBeat All Access to unlock brokerage rankingsJosh SchimmerSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingOverweight$55.00+38.61%10/7/2025 Bloom BurtonSubscribe to MarketBeat All Access to unlock brokerage rankings UpgradeStrong-Buy10/7/2025 William BlairSubscribe to MarketBeat All Access to unlock brokerage rankings Reiterated RatingOutperform5/14/2025 EvercoreSubscribe to MarketBeat All Access to unlock brokerage rankingsCory KasimovSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageOutperform$55.00+87.62%4/17/2025 The Goldman Sachs GroupSubscribe to MarketBeat All Access to unlock brokerage rankingsPaul ChoiSubscribe to MarketBeat All Access to unlock analyst rankingsLower TargetBuy$60.00 ➝ $52.00+47.57%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 09:51 PM ET. XENE Forecast - Frequently Asked Questions What is Xenon Pharmaceuticals' forecast for 2026? According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Xenon Pharmaceuticals is $70.14, with a high forecast of $97.00 and a low forecast of $46.00. Should I buy or sell Xenon Pharmaceuticals stock right now? 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last twelve months. There is currently 1 sell rating, 1 hold rating, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" XENE shares. Does Xenon Pharmaceuticals's stock price have much upside? According to analysts, Xenon Pharmaceuticals's stock has a predicted upside of 98.48% based on their 12-month stock forecasts. Has Xenon Pharmaceuticals been downgraded by Wall Street analysts recently? Over the previous 90 days, Xenon Pharmaceuticals's stock had 1 downgrade by analysts. What analysts cover Xenon Pharmaceuticals? Xenon Pharmaceuticals has been rated by research analysts at Deutsche Bank Aktiengesellschaft, Guggenheim, HC Wainwright, Jefferies Financial Group, Needham & Company LLC, Robert W. Baird, Royal Bank Of Canada, Wedbush, Weiss Ratings, and Wells Fargo & Company in the past 90 days. Do Wall Street analysts like Xenon Pharmaceuticals more than its competitors? Analysts like Xenon Pharmaceuticals more than other "healthcare" companies. The consensus rating for Xenon Pharmaceuticals is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how XENE compares to other companies. Stock Forecasts and Research Tools Related Companies SMMT Stock Forecast BMRN Stock Forecast MDGL Stock Forecast IBRX Stock Forecast PCVX Stock Forecast KRYS Stock Forecast KYMR Stock Forecast PTGX Stock Forecast TGTX Stock Forecast SYRE Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Xenon Pharmaceuticals RecommendationsWall Street ZenGuggenheimWeiss RatingsJefferies Financial GroupWells Fargo & CompanyNeedham & Company LLCRoyal Bank Of CanadaWedbushHC WainwrightDeutsche Bank AktiengesellschaftRobert W. BairdJPMorgan Chase & Co.Morgan StanleyBank of AmericaWolfe Research MarketBeat monitors more than a dozen sources for Xenon Pharmaceuticals analyst ratings, with the most recent rating issued on 10/6/2026. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredSpaceX is worth trillions. This one's $14.It is not SpaceX, Tesla, Starlink, or Neuralink. But Elon's rocket company shows up in this stock's paperwork,...Behind the Markets | SponsoredWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredMissed this in 2024? Here’s your second chanceIn April 2024, gold had gone nowhere for 13 years - then it surged to a record high, more than doubling in val...Traders Agency | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenon Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
